Leukapheresis Market By Product (Devices, Disposables), By Method (Centrifugation, Membrane Separation, Selective Adsorption), By Application (Therapeutic Applications, Research Applications), By End User (Blood Centers, Hospitals, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global leukapheresis market was valued at $245.65 million in 2021 and is projected to reach $561.64 million by 2031 registering a CAGR of 8.6% from 2022 to 2031.
Leukapheresis is a laboratory procedure in which white blood cells are removed from a sample of blood. In this process, blood passes through a machine that takes out white blood cells and returns all other blood cells and plasma back into the bloodstream. In addition, the process includes insertion of two intravenous (IV) lines into body. One IV line removes blood while the other carries cleaned blood back to the body. This procedure takes approximately two to three hours to complete.
The growth of global leukapheresis market is majorly driven by increase in demand for leukapheresis, owing to increase in incidences and prevalence of leukemia. In addition, increase in demand for blood donations and rise in demand for leukopaks in clinical research studies responsible for the market growth. Furthermore, increase in awareness regarding leukapheresis procedures in developed countries such as the U.S. further fuel the market growth. However high cost associated with leukapheresis therapeutics and leukopak and blood transfusion safety in developing countries hinder the market growth. Conversely, increase in demand for leukapheresis in pediatric patients is anticipated to provide lucrative opportunities to the market players.
The global leukapheresis market is segmented into product, method, application, end user, and region. By product, the market is categorized into devices and disposables. On the basis of method, it is segregated into centrifugation, membrane separation, and selective adsorption. By application, it is classified into therapeutics application and research application. On the basis of end user, it is categorized into blood centers, hospitals, and others. The others segment further includes research institutes, biopharmaceutical manufacturers, and private medical settings. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the leukapheresis market analysis from 2021 to 2031 to identify the prevailing leukapheresis market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the leukapheresis market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global leukapheresis market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
Devices
Disposables
By Method
Centrifugation
Membrane Separation
Selective Adsorption
By Application
Research Applications
Therapeutic Applications
By End User
Blood Centers
Hospitals
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Italy
Spain
Rest of Europe
Germany
France
UK
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Adacyte Therapeutics
AllCells, LLC.
Asahi Kasei Corporation
Charles River Laboratories International, Inc.
Cerus Corporation
Fresenius Kabi
Haemonetics Corporation
Macopharma
SB-Kawasumi Laboratories, Inc.
Terumo BCT, Inc.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: LEUKAPHERESIS MARKET, BY PRODUCT
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Devices
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Disposables
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- CHAPTER 5: LEUKAPHERESIS MARKET, BY METHOD
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Centrifugation
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Membrane Separation
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Selective Adsorption
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- CHAPTER 6: LEUKAPHERESIS MARKET, BY APPLICATION
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Therapeutic Applications
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Research Applications
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- CHAPTER 7: LEUKAPHERESIS MARKET, BY END USER
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 Blood Centers
- 7.2.1 Key market trends, growth factors and opportunities
- 7.2.2 Market size and forecast, by region
- 7.2.3 Market analysis by country
- 7.3 Hospitals
- 7.3.1 Key market trends, growth factors and opportunities
- 7.3.2 Market size and forecast, by region
- 7.3.3 Market analysis by country
- 7.4 Others
- 7.4.1 Key market trends, growth factors and opportunities
- 7.4.2 Market size and forecast, by region
- 7.4.3 Market analysis by country
- CHAPTER 8: LEUKAPHERESIS MARKET, BY REGION
- 8.1 Overview
- 8.1.1 Market size and forecast
- 8.2 North America
- 8.2.1 Key trends and opportunities
- 8.2.2 North America Market size and forecast, by Product
- 8.2.3 North America Market size and forecast, by Method
- 8.2.4 North America Market size and forecast, by Application
- 8.2.5 North America Market size and forecast, by End User
- 8.2.6 North America Market size and forecast, by country
- 8.2.6.1 U.S.
- 8.2.6.1.1 Market size and forecast, by Product
- 8.2.6.1.2 Market size and forecast, by Method
- 8.2.6.1.3 Market size and forecast, by Application
- 8.2.6.1.4 Market size and forecast, by End User
- 8.2.6.2 Canada
- 8.2.6.2.1 Market size and forecast, by Product
- 8.2.6.2.2 Market size and forecast, by Method
- 8.2.6.2.3 Market size and forecast, by Application
- 8.2.6.2.4 Market size and forecast, by End User
- 8.2.6.3 Mexico
- 8.2.6.3.1 Market size and forecast, by Product
- 8.2.6.3.2 Market size and forecast, by Method
- 8.2.6.3.3 Market size and forecast, by Application
- 8.2.6.3.4 Market size and forecast, by End User
- 8.3 Europe
- 8.3.1 Key trends and opportunities
- 8.3.2 Europe Market size and forecast, by Product
- 8.3.3 Europe Market size and forecast, by Method
- 8.3.4 Europe Market size and forecast, by Application
- 8.3.5 Europe Market size and forecast, by End User
- 8.3.6 Europe Market size and forecast, by country
- 8.3.6.1 Germany
- 8.3.6.1.1 Market size and forecast, by Product
- 8.3.6.1.2 Market size and forecast, by Method
- 8.3.6.1.3 Market size and forecast, by Application
- 8.3.6.1.4 Market size and forecast, by End User
- 8.3.6.2 France
- 8.3.6.2.1 Market size and forecast, by Product
- 8.3.6.2.2 Market size and forecast, by Method
- 8.3.6.2.3 Market size and forecast, by Application
- 8.3.6.2.4 Market size and forecast, by End User
- 8.3.6.3 UK
- 8.3.6.3.1 Market size and forecast, by Product
- 8.3.6.3.2 Market size and forecast, by Method
- 8.3.6.3.3 Market size and forecast, by Application
- 8.3.6.3.4 Market size and forecast, by End User
- 8.3.6.4 Italy
- 8.3.6.4.1 Market size and forecast, by Product
- 8.3.6.4.2 Market size and forecast, by Method
- 8.3.6.4.3 Market size and forecast, by Application
- 8.3.6.4.4 Market size and forecast, by End User
- 8.3.6.5 Spain
- 8.3.6.5.1 Market size and forecast, by Product
- 8.3.6.5.2 Market size and forecast, by Method
- 8.3.6.5.3 Market size and forecast, by Application
- 8.3.6.5.4 Market size and forecast, by End User
- 8.3.6.6 Rest of Europe
- 8.3.6.6.1 Market size and forecast, by Product
- 8.3.6.6.2 Market size and forecast, by Method
- 8.3.6.6.3 Market size and forecast, by Application
- 8.3.6.6.4 Market size and forecast, by End User
- 8.4 Asia-Pacific
- 8.4.1 Key trends and opportunities
- 8.4.2 Asia-Pacific Market size and forecast, by Product
- 8.4.3 Asia-Pacific Market size and forecast, by Method
- 8.4.4 Asia-Pacific Market size and forecast, by Application
- 8.4.5 Asia-Pacific Market size and forecast, by End User
- 8.4.6 Asia-Pacific Market size and forecast, by country
- 8.4.6.1 Japan
- 8.4.6.1.1 Market size and forecast, by Product
- 8.4.6.1.2 Market size and forecast, by Method
- 8.4.6.1.3 Market size and forecast, by Application
- 8.4.6.1.4 Market size and forecast, by End User
- 8.4.6.2 China
- 8.4.6.2.1 Market size and forecast, by Product
- 8.4.6.2.2 Market size and forecast, by Method
- 8.4.6.2.3 Market size and forecast, by Application
- 8.4.6.2.4 Market size and forecast, by End User
- 8.4.6.3 India
- 8.4.6.3.1 Market size and forecast, by Product
- 8.4.6.3.2 Market size and forecast, by Method
- 8.4.6.3.3 Market size and forecast, by Application
- 8.4.6.3.4 Market size and forecast, by End User
- 8.4.6.4 Australia
- 8.4.6.4.1 Market size and forecast, by Product
- 8.4.6.4.2 Market size and forecast, by Method
- 8.4.6.4.3 Market size and forecast, by Application
- 8.4.6.4.4 Market size and forecast, by End User
- 8.4.6.5 South Korea
- 8.4.6.5.1 Market size and forecast, by Product
- 8.4.6.5.2 Market size and forecast, by Method
- 8.4.6.5.3 Market size and forecast, by Application
- 8.4.6.5.4 Market size and forecast, by End User
- 8.4.6.6 Rest of Asia-Pacific
- 8.4.6.6.1 Market size and forecast, by Product
- 8.4.6.6.2 Market size and forecast, by Method
- 8.4.6.6.3 Market size and forecast, by Application
- 8.4.6.6.4 Market size and forecast, by End User
- 8.5 LAMEA
- 8.5.1 Key trends and opportunities
- 8.5.2 LAMEA Market size and forecast, by Product
- 8.5.3 LAMEA Market size and forecast, by Method
- 8.5.4 LAMEA Market size and forecast, by Application
- 8.5.5 LAMEA Market size and forecast, by End User
- 8.5.6 LAMEA Market size and forecast, by country
- 8.5.6.1 Brazil
- 8.5.6.1.1 Market size and forecast, by Product
- 8.5.6.1.2 Market size and forecast, by Method
- 8.5.6.1.3 Market size and forecast, by Application
- 8.5.6.1.4 Market size and forecast, by End User
- 8.5.6.2 Saudi Arabia
- 8.5.6.2.1 Market size and forecast, by Product
- 8.5.6.2.2 Market size and forecast, by Method
- 8.5.6.2.3 Market size and forecast, by Application
- 8.5.6.2.4 Market size and forecast, by End User
- 8.5.6.3 South Africa
- 8.5.6.3.1 Market size and forecast, by Product
- 8.5.6.3.2 Market size and forecast, by Method
- 8.5.6.3.3 Market size and forecast, by Application
- 8.5.6.3.4 Market size and forecast, by End User
- 8.5.6.4 Rest of LAMEA
- 8.5.6.4.1 Market size and forecast, by Product
- 8.5.6.4.2 Market size and forecast, by Method
- 8.5.6.4.3 Market size and forecast, by Application
- 8.5.6.4.4 Market size and forecast, by End User
- CHAPTER 9: COMPANY LANDSCAPE
- 9.1. Introduction
- 9.2. Top winning strategies
- 9.3. Product Mapping of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Key developments
- CHAPTER 10: COMPANY PROFILES
- 10.1 Adacyte Therapeutics
- 10.1.1 Company overview
- 10.1.2 Company snapshot
- 10.1.3 Operating business segments
- 10.1.4 Product portfolio
- 10.1.5 Business performance
- 10.1.6 Key strategic moves and developments
- 10.2 AllCells, LLC.
- 10.2.1 Company overview
- 10.2.2 Company snapshot
- 10.2.3 Operating business segments
- 10.2.4 Product portfolio
- 10.2.5 Business performance
- 10.2.6 Key strategic moves and developments
- 10.3 Asahi Kasei Corporation
- 10.3.1 Company overview
- 10.3.2 Company snapshot
- 10.3.3 Operating business segments
- 10.3.4 Product portfolio
- 10.3.5 Business performance
- 10.3.6 Key strategic moves and developments
- 10.4 Charles River Laboratories International, Inc.
- 10.4.1 Company overview
- 10.4.2 Company snapshot
- 10.4.3 Operating business segments
- 10.4.4 Product portfolio
- 10.4.5 Business performance
- 10.4.6 Key strategic moves and developments
- 10.5 Cerus Corporation
- 10.5.1 Company overview
- 10.5.2 Company snapshot
- 10.5.3 Operating business segments
- 10.5.4 Product portfolio
- 10.5.5 Business performance
- 10.5.6 Key strategic moves and developments
- 10.6 Fresenius Kabi
- 10.6.1 Company overview
- 10.6.2 Company snapshot
- 10.6.3 Operating business segments
- 10.6.4 Product portfolio
- 10.6.5 Business performance
- 10.6.6 Key strategic moves and developments
- 10.7 Haemonetics Corporation
- 10.7.1 Company overview
- 10.7.2 Company snapshot
- 10.7.3 Operating business segments
- 10.7.4 Product portfolio
- 10.7.5 Business performance
- 10.7.6 Key strategic moves and developments
- 10.8 Macopharma
- 10.8.1 Company overview
- 10.8.2 Company snapshot
- 10.8.3 Operating business segments
- 10.8.4 Product portfolio
- 10.8.5 Business performance
- 10.8.6 Key strategic moves and developments
- 10.9 SB-Kawasumi Laboratories, Inc.
- 10.9.1 Company overview
- 10.9.2 Company snapshot
- 10.9.3 Operating business segments
- 10.9.4 Product portfolio
- 10.9.5 Business performance
- 10.9.6 Key strategic moves and developments
- 10.10 Terumo BCT, Inc.
- 10.10.1 Company overview
- 10.10.2 Company snapshot
- 10.10.3 Operating business segments
- 10.10.4 Product portfolio
- 10.10.5 Business performance
- 10.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 2. LEUKAPHERESIS MARKET, FOR DEVICES, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. LEUKAPHERESIS MARKET FOR DEVICES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. LEUKAPHERESIS MARKET, FOR DISPOSABLES, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. LEUKAPHERESIS MARKET FOR DISPOSABLES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. GLOBAL LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 7. LEUKAPHERESIS MARKET, FOR CENTRIFUGATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 8. LEUKAPHERESIS MARKET FOR CENTRIFUGATION, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 9. LEUKAPHERESIS MARKET, FOR MEMBRANE SEPARATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. LEUKAPHERESIS MARKET FOR MEMBRANE SEPARATION, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 11. LEUKAPHERESIS MARKET, FOR SELECTIVE ADSORPTION, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. LEUKAPHERESIS MARKET FOR SELECTIVE ADSORPTION, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 13. GLOBAL LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 14. LEUKAPHERESIS MARKET, FOR THERAPEUTIC APPLICATIONS, BY REGION, 2021-2031 ($MILLION)
- TABLE 15. LEUKAPHERESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 16. LEUKAPHERESIS MARKET, FOR RESEARCH APPLICATIONS, BY REGION, 2021-2031 ($MILLION)
- TABLE 17. LEUKAPHERESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 18. GLOBAL LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 19. LEUKAPHERESIS MARKET, FOR BLOOD CENTERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 20. LEUKAPHERESIS MARKET FOR BLOOD CENTERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 21. LEUKAPHERESIS MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
- TABLE 22. LEUKAPHERESIS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 23. LEUKAPHERESIS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 24. LEUKAPHERESIS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 25. LEUKAPHERESIS MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 26. NORTH AMERICA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 27. NORTH AMERICA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 28. NORTH AMERICA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 29. NORTH AMERICA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 30. NORTH AMERICA LEUKAPHERESIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 31. U.S. LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 32. U.S. LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 33. U.S. LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 34. U.S. LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 35. CANADA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 36. CANADA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 37. CANADA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 38. CANADA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 39. MEXICO LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 40. MEXICO LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 41. MEXICO LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 42. MEXICO LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 43. EUROPE LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 44. EUROPE LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 45. EUROPE LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 46. EUROPE LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 47. EUROPE LEUKAPHERESIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 48. GERMANY LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 49. GERMANY LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 50. GERMANY LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 51. GERMANY LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 52. FRANCE LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 53. FRANCE LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 54. FRANCE LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 55. FRANCE LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 56. UK LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 57. UK LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 58. UK LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 59. UK LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 60. ITALY LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 61. ITALY LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 62. ITALY LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 63. ITALY LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 64. SPAIN LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 65. SPAIN LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 66. SPAIN LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 67. SPAIN LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 68. REST OF EUROPE LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 69. REST OF EUROPE LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 70. REST OF EUROPE LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 71. REST OF EUROPE LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 72. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 73. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 74. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 75. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 76. ASIA-PACIFIC LEUKAPHERESIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 77. JAPAN LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 78. JAPAN LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 79. JAPAN LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 80. JAPAN LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 81. CHINA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 82. CHINA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 83. CHINA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 84. CHINA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 85. INDIA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 86. INDIA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 87. INDIA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 88. INDIA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 89. AUSTRALIA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 90. AUSTRALIA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 91. AUSTRALIA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 92. AUSTRALIA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 93. SOUTH KOREA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 94. SOUTH KOREA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 95. SOUTH KOREA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 96. SOUTH KOREA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 97. REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 98. REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 99. REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 100. REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 101. LAMEA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 102. LAMEA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 103. LAMEA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 104. LAMEA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 105. LAMEA LEUKAPHERESIS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 106. BRAZIL LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 107. BRAZIL LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 108. BRAZIL LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 109. BRAZIL LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 110. SAUDI ARABIA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 111. SAUDI ARABIA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 112. SAUDI ARABIA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 113. SAUDI ARABIA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 114. SOUTH AFRICA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 115. SOUTH AFRICA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 116. SOUTH AFRICA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 117. SOUTH AFRICA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 118. REST OF LAMEA LEUKAPHERESIS MARKET, BY PRODUCT, 2021-2031 ($MILLION)
- TABLE 119. REST OF LAMEA LEUKAPHERESIS MARKET, BY METHOD, 2021-2031 ($MILLION)
- TABLE 120. REST OF LAMEA LEUKAPHERESIS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 121. REST OF LAMEA LEUKAPHERESIS MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 122.ADACYTE THERAPEUTICS: COMPANY SNAPSHOT
- TABLE 123.ADACYTE THERAPEUTICS: OPERATING SEGMENTS
- TABLE 124.ADACYTE THERAPEUTICS: PRODUCT PORTFOLIO
- TABLE 125.ADACYTE THERAPEUTICS: NET SALES,
- TABLE 126.ADACYTE THERAPEUTICS: KEY STRATERGIES
- TABLE 127.ALLCELLS, LLC.: COMPANY SNAPSHOT
- TABLE 128.ALLCELLS, LLC.: OPERATING SEGMENTS
- TABLE 129.ALLCELLS, LLC.: PRODUCT PORTFOLIO
- TABLE 130.ALLCELLS, LLC.: NET SALES,
- TABLE 131.ALLCELLS, LLC.: KEY STRATERGIES
- TABLE 132.ASAHI KASEI CORPORATION: COMPANY SNAPSHOT
- TABLE 133.ASAHI KASEI CORPORATION: OPERATING SEGMENTS
- TABLE 134.ASAHI KASEI CORPORATION: PRODUCT PORTFOLIO
- TABLE 135.ASAHI KASEI CORPORATION: NET SALES,
- TABLE 136.ASAHI KASEI CORPORATION: KEY STRATERGIES
- TABLE 137.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT
- TABLE 138.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: OPERATING SEGMENTS
- TABLE 139.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRODUCT PORTFOLIO
- TABLE 140.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: NET SALES,
- TABLE 141.CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY STRATERGIES
- TABLE 142.CERUS CORPORATION: COMPANY SNAPSHOT
- TABLE 143.CERUS CORPORATION: OPERATING SEGMENTS
- TABLE 144.CERUS CORPORATION: PRODUCT PORTFOLIO
- TABLE 145.CERUS CORPORATION: NET SALES,
- TABLE 146.CERUS CORPORATION: KEY STRATERGIES
- TABLE 147.FRESENIUS KABI: COMPANY SNAPSHOT
- TABLE 148.FRESENIUS KABI: OPERATING SEGMENTS
- TABLE 149.FRESENIUS KABI: PRODUCT PORTFOLIO
- TABLE 150.FRESENIUS KABI: NET SALES,
- TABLE 151.FRESENIUS KABI: KEY STRATERGIES
- TABLE 152.HAEMONETICS CORPORATION: COMPANY SNAPSHOT
- TABLE 153.HAEMONETICS CORPORATION: OPERATING SEGMENTS
- TABLE 154.HAEMONETICS CORPORATION: PRODUCT PORTFOLIO
- TABLE 155.HAEMONETICS CORPORATION: NET SALES,
- TABLE 156.HAEMONETICS CORPORATION: KEY STRATERGIES
- TABLE 157.MACOPHARMA: COMPANY SNAPSHOT
- TABLE 158.MACOPHARMA: OPERATING SEGMENTS
- TABLE 159.MACOPHARMA: PRODUCT PORTFOLIO
- TABLE 160.MACOPHARMA: NET SALES,
- TABLE 161.MACOPHARMA: KEY STRATERGIES
- TABLE 162.SB-KAWASUMI LABORATORIES, INC.: COMPANY SNAPSHOT
- TABLE 163.SB-KAWASUMI LABORATORIES, INC.: OPERATING SEGMENTS
- TABLE 164.SB-KAWASUMI LABORATORIES, INC.: PRODUCT PORTFOLIO
- TABLE 165.SB-KAWASUMI LABORATORIES, INC.: NET SALES,
- TABLE 166.SB-KAWASUMI LABORATORIES, INC.: KEY STRATERGIES
- TABLE 167.TERUMO BCT, INC.: COMPANY SNAPSHOT
- TABLE 168.TERUMO BCT, INC.: OPERATING SEGMENTS
- TABLE 169.TERUMO BCT, INC.: PRODUCT PORTFOLIO
- TABLE 170.TERUMO BCT, INC.: NET SALES,
- TABLE 171.TERUMO BCT, INC.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.LEUKAPHERESIS MARKET SEGMENTATION
- FIGURE 2.LEUKAPHERESIS MARKET,2021-2031
- FIGURE 3.LEUKAPHERESIS MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.LEUKAPHERESIS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.LEUKAPHERESIS MARKET,BY PRODUCT,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF DEVICES LEUKAPHERESIS MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF DISPOSABLES LEUKAPHERESIS MARKET,2021-2031(%)
- FIGURE 15.LEUKAPHERESIS MARKET,BY METHOD,2021(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CENTRIFUGATION LEUKAPHERESIS MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF MEMBRANE SEPARATION LEUKAPHERESIS MARKET,2021-2031(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF SELECTIVE ADSORPTION LEUKAPHERESIS MARKET,2021-2031(%)
- FIGURE 19.LEUKAPHERESIS MARKET,BY APPLICATION,2021(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC APPLICATIONS LEUKAPHERESIS MARKET,2021-2031(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF RESEARCH APPLICATIONS LEUKAPHERESIS MARKET,2021-2031(%)
- FIGURE 22.LEUKAPHERESIS MARKET,BY END USER,2021(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF BLOOD CENTERS LEUKAPHERESIS MARKET,2021-2031(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HOSPITALS LEUKAPHERESIS MARKET,2021-2031(%)
- FIGURE 25.COMPARATIVE SHARE ANALYSIS OF OTHERS LEUKAPHERESIS MARKET,2021-2031(%)
- FIGURE 26.LEUKAPHERESIS MARKET BY REGION,2021
- FIGURE 27.U.S. LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 28.CANADA LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 29.MEXICO LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 30.GERMANY LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 31.FRANCE LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 32.UK LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 33.ITALY LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 34.SPAIN LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 35.REST OF EUROPE LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 36.JAPAN LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 37.CHINA LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 38.INDIA LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 39.AUSTRALIA LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 40.SOUTH KOREA LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 41.REST OF ASIA-PACIFIC LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 42.BRAZIL LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 43.SAUDI ARABIA LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 44.SOUTH AFRICA LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 45.REST OF LAMEA LEUKAPHERESIS MARKET,2021-2031($MILLION)
- FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 50.COMPETITIVE DASHBOARD
- FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 52.ADACYTE THERAPEUTICS.: NET SALES ,($MILLION)
- FIGURE 53.ALLCELLS, LLC..: NET SALES ,($MILLION)
- FIGURE 54.ASAHI KASEI CORPORATION.: NET SALES ,($MILLION)
- FIGURE 55.CHARLES RIVER LABORATORIES INTERNATIONAL, INC..: NET SALES ,($MILLION)
- FIGURE 56.CERUS CORPORATION.: NET SALES ,($MILLION)
- FIGURE 57.FRESENIUS KABI.: NET SALES ,($MILLION)
- FIGURE 58.HAEMONETICS CORPORATION.: NET SALES ,($MILLION)
- FIGURE 59.MACOPHARMA.: NET SALES ,($MILLION)
- FIGURE 60.SB-KAWASUMI LABORATORIES, INC..: NET SALES ,($MILLION)
- FIGURE 61.TERUMO BCT, INC..: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook